SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
EVH, PFE among premarket losers
Seeking Alpha - Article · 5d ago
72 Biggest Movers From Friday
Gainers Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares jumped 127.8% to close at $11.07 on Friday after the company announced updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting.
Benzinga · 5d ago
Mid-Afternoon Market Update: U.S. Stocks Turn Positive; Crude Oil Surges Over 5%
Toward the end of trading Friday, the Dow traded up 0.31% to 25478.86 while the NASDAQ rose 0.99% to 9461.91. The S&P also rose, gaining 0.50% to 3044.82.
Benzinga · 05/29 19:10
ZS, AGEN, CGC and MGNX among midday movers
Seeking Alpha - Article · 05/29 16:43
50 Stocks Moving In Friday's Mid-Day Session
Benzinga · 05/29 16:15
Mid-Day Market Update: Canopy Growth Slides After Q4 Results; Sonoma Pharmaceuticals Shares Surge
Midway through trading Friday, the Dow traded down 0.71% to 25221.42 while the NASDAQ fell 0.08% to 9361.25. The S&P also fell, dropping 0.46% to 3015.85.
Benzinga · 05/29 16:00
Mid-Morning Market Update: Markets Open Lower; Big Lots Beats Q1 Estimates
Following the market opening Friday, the Dow traded down 0.57% to 25256.94 while the NASDAQ fell 0.20% to 9350.01. The S&P also fell, dropping 0.41% to 3017.18.
Benzinga · 05/29 14:22
VMW, MRVL among premarket gainers
Seeking Alpha - Article · 05/29 13:21
Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
PR Newswire · 05/29 13:00
Phio Pharma +14% on positive data from Intasyl programs
Seeking Alpha - Article · 05/29 12:12
PHIO: Intasyl Advantage vs. Gene Editing
Zacks Small Cap Research · 05/29 10:38
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49
Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced data analyzing the applicability of
PR Newswire · 05/14 20:05
Phio Pharmaceuticals reports Q1 results
Phio Pharmaceuticals (NASDAQ:PHIO): Q1 GAAP EPS of -$1.33. Cash of $13.3M. Press Release
seekingalpha · 05/13 01:45
Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
PR Newswire · 05/12 21:38
Phio Pharmaceuticals Q1 EPS $(1.330) Down From $(0.100) YoY
Phio Pharmaceuticals (NASDAQ:PHIO) reported quarterly losses of $(1.330) per share. This is a 1230 percent decrease over losses of $(0.100) per share from the same period last year.
Benzinga · 05/12 20:41
Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020
PR Newswire · 05/04 12:30
Phio Pharma Shares Tick Higher On Volume; Traders Circulate US PTO Abstract For Co.'s 'Modified RNAi polynucleotides and uses thereof'
Benzinga · 04/28 15:00
PHIO: Collaborations Provide Several Options
Zacks Small Cap Research · 04/07 11:05
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU)
Benzinga · 04/03 11:36